scholarly journals Trends in the Causes of Death among Kidney Transplant Recipients in the United States (1996–2014)

2018 ◽  
Vol 48 (6) ◽  
pp. 472-481 ◽  
Author(s):  
Ahmed A. Awan ◽  
Jingbo Niu ◽  
Jenny S. Pan ◽  
Kevin F. Erickson ◽  
Sreedhar Mandayam ◽  
...  
Keyword(s):  
United States ◽  
Kidney Transplant ◽  
Cardiovascular Mortality ◽  
Causes Of Death ◽  
Graft Loss ◽  
Graft Function ◽  
The United States ◽  
Mortality Data ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

Background: Death with graft function remains an important cause of graft loss among kidney transplant recipients (KTRs). Little is known about the trend of specific causes of death in KTRs in recent years. Methods: We analyzed United States Renal Data System data (1996–2014) to determine 1- and 10-year all-cause and cause-specific mortality in adult KTRs who died with a functioning allograft. We also studied 1- and 10-year trends in the various causes of mortality. Results: Of 210,327 KTRs who received their first kidney transplant from 1996 to 2014, 3.2% died within 1 year after transplant. Cardiovascular deaths constituted the majority (24.7%), followed by infectious (15.2%) and malignant (2.9%) causes; 40.1% of deaths had no reported cause. Using 1996 as the referent year, all-cause as well as cardiovascular mortality declined, whereas mortality due to malignancy did not. For analyses of 10-year mortality, we studied 94,384 patients who received a first kidney transplant from 1996 to 2005. Of those, 22.1% died over 10 years and the causative patterns of their causes of death were similar to those associated with 1-year mortality. Conclusions: Despite the downtrend in mortality over the last 2 decades, a significant percentage of KTRs die in 10-years with a functioning graft, and cardiovascular mortality remains the leading cause of death. These data also highlight the need for diligent collection of mortality data in KTRs.

Metformin Use in Kidney Transplant Recipients Throughout the United States.

2014 ◽  
Vol 98 ◽  
pp. 525
Author(s):  
J. Stephen ◽  
T. Anderson-Haag ◽  
S. Gustafson ◽  
J. Snyder ◽  
A. Israni ◽  
...  
Keyword(s):  
United States ◽  
Kidney Transplant ◽  
The United States ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

Metformin Use in Kidney Transplant Recipients in the United States: An Observational Study

2014 ◽  
Vol 40 (6) ◽  
pp. 546-553 ◽  
Author(s):  
Jenise Stephen ◽  
Teresa L. Anderson-Haag ◽  
Sally Gustafson ◽  
Jon J. Snyder ◽  
Bertram L. Kasiske ◽  
...  
Keyword(s):  
United States ◽  
Observational Study ◽  
Kidney Transplant ◽  
The United States ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

Clinical Management of Kidney Transplant Recipients

2019 ◽  
pp. 457-459
Author(s):  
James A. Onigkeit
Keyword(s):  
United States ◽  
Transplant Recipient ◽  
Kidney Transplant ◽  
Clinical Management ◽  
Living Donor ◽  
Kidney Transplant Recipient ◽  
Deceased Donor ◽  
The United States ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

Kidney transplant is common. More than 19,000 kidney transplants were performed in the United States in 2017. About two-thirds were deceased donor transplants, and about one-third were living donor transplants. The clinical management of a kidney transplant recipient begins in the operating room. Posttransplant complications can be divided into 2 categories: surgical and medical.

scholarly journals Emergency department use among kidney transplant recipients in the United States

2017 ◽  
Vol 18 (4) ◽  
pp. 868-880 ◽  
Author(s):  
Brendan P. Lovasik ◽  
Rebecca Zhang ◽  
Jason M. Hockenberry ◽  
Justin D. Schrager ◽  
Stephen O. Pastan ◽  
...  
Keyword(s):  
United States ◽  
Emergency Department ◽  
Kidney Transplant ◽  
The United States ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Emergency Department Use

scholarly journals Improving Transplant Medication Safety Through a Pharmacist-Empowered, Patient-Centered, mHealth-Based Intervention: TRANSAFE Rx Study Protocol (Preprint)

2017 ◽  
Author(s):  
James N Fleming ◽  
Frank Treiber ◽  
John McGillicuddy ◽  
Mulugeta Gebregziabher ◽  
David J Taber
Keyword(s):  
Clinical Trial ◽  
Kidney Transplant ◽  
Outcome Measures ◽  
Medication Safety ◽  
Graft Loss ◽  
Graft Function ◽  
Economic Effectiveness ◽  
Controlled Clinical Trial ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

BACKGROUND Medication errors, adverse drug events, and nonadherence are the predominant causes of graft loss in kidney transplant recipients and lead to increased healthcare utilization. Research has demonstrated that clinical pharmacists have the unique education and training to identify these events early and develop strategies to mitigate or prevent downstream sequelae. In addition, studies utilizing mHealth interventions have demonstrated success in improving the control of chronic conditions that lead to kidney transplant deterioration. OBJECTIVE The goal of the prospective, randomized TRANSAFE Rx study is to measure the clinical and economic effectiveness of a pharmacist-led, mHealth-based intervention, as compared to usual care, in kidney transplant recipients. METHODS TRANSAFE Rx is a 12-month, parallel, two-arm, 1:1 randomized controlled clinical trial involving 136 participants (68 in each arm) and measuring the clinical and economic effectiveness of a pharmacist-led intervention which utilizes an innovative mobile health application to improve medication safety and health outcomes, as compared to usual posttransplant care. RESULTS The primary outcome measure of this study will be the incidence and severity of MEs and ADRs, which will be identified, categorized, and compared between the intervention and control cohorts. The exploratory outcome measures of this study are to compare the incidence and severity of acute rejections, infections, graft function, graft loss, and death between research cohorts and measure the association between medication safety issues and these events. Additional data that will be gathered includes sociodemographics, health literacy, depression, and support. CONCLUSIONS With this report we describe the study design, methods, and outcome measures that will be utilized in the ongoing TRANSAFE Rx clinical trial. CLINICALTRIAL ClinicalTrials.gov NCT03247322: https://clinicaltrials.gov/ct2/show/NCT03247322 (Archived by WebCite at http://www.webcitation.org/6xcSUnuzW)

Temporal trends and current use of de‐novo belatacept in kidney transplant recipients in the United States

2021 ◽  
Author(s):  
Geeta Karadkhele ◽  
Charlotte Duneton ◽  
Rouba Garro ◽  
Idelberto Raul Badell ◽  
Thomas C. Pearson ◽  
...  
Keyword(s):  
United States ◽  
Kidney Transplant ◽  
De Novo ◽  
Temporal Trends ◽  
The United States ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients
Sign in / Sign up

Export Citation Format

Share Document